Conference Correspondent

Beth Faiman gets questions from her patients about daratumumab on an almost daily basis. Find out what their most asked questions are.
Patients with newly diagnosed multiple myeloma have different needs than pateints relapsed/refractory disease, and Beth Faiman addresses what some of these needs are.
Beth Faiman explains how she identfies side effects that her patients are experiencing in order to open the lines of communication to better address other issues the patient may not be aware of.
Beth Faiman discusses why it's important to communicate with and educate patients so that they can better manage their symptoms before they become more severe.
Beth Faiman expresses her main concerns regarding new treatments being studied to treat multiple myeloma.
Beth Faiman identifies how the Janssen CarePath program can financially help anyone who is diagnosed with multiple myeloma and requires daratumumab.
As patients with multiple myeloma are now living longer, survivorship care is becoming more crucial.
Leslie Lauersdorf addresses the challenges associated with staying abreast of the side effects, management, and sequencing for new multiple myeloma treatments.
Leslie Lauersdorf discusses the need to balance optimism and realism in caring for patients with relapsed/refractory multiple myeloma.
Leslie Lauersdorf insist that it's vital to inform your patients about what's involved in beginning daratumumab treatments, especially because of the lengthy chair time.
Page 3 of 12
Results 21 - 30 of 117